The Marginal Zone Lymphoma Drug Pipeline Analysis highlights the development of innovative therapies targeting marginal zone lymphoma (MZL), a rare and indolent type of non-Hodgkin lymphoma. With limited treatment options and a tendency for relapse, pharmaceutical companies are advancing targeted therapies such as BTK inhibitors, monoclonal antibodies, and novel immunomodulators. Risi... https://www.expertmarketresearch.com/clinical-trials/marginal-zone-lymphoma-drug-pipeline-insight